Genelux (GNLX) Other Working Capital Changes (2022 - 2026)
Genelux (GNLX) posted Other Working Capital Changes of -$87000.0 for Q1 2026, up 6.45% on a QoQ basis from -$93000.0 in Q4 2025, and down 150.88% year-over-year from $171000.0 in Q1 2025.
Analysis
Genelux (GNLX) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Genelux has reported Other Working Capital Changes for 5 years, with the latest figure at -$87000.0 in Q1 2026.
- On a quarterly basis, Other Working Capital Changes fell 150.88% year-over-year to -$87000.0 in Q1 2026; TTM through Mar 2026 was -$595000.0, a 43.06% increase from a year earlier, with the FY2025 full-year figure at -$337000.0, up 48.23% from the prior year.
- Other Working Capital Changes was -$87000.0 for Q1 2026 at Genelux, up from -$93000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $5.5 million in Q1 2022, with the low at -$1.2 million in Q4 2024.
- Average Other Working Capital Changes over 5 years is $264800.0, with a median of -$87000.0 recorded in 2026.
- The largest YoY upside for Other Working Capital Changes was 630.12% in 2024 against a maximum downside of 1225.0% in 2024.
- Over 5 years, Other Working Capital Changes stood at $110000.0 in 2022, then tumbled by 183.64% to -$92000.0 in 2023, then plunged by 1225.0% to -$1.2 million in 2024, then surged by 92.37% to -$93000.0 in 2025, then grew by 6.45% to -$87000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$87000.0 (Q1 2026), -$93000.0 (Q4 2025), and -$834000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -87,000.00 |
| Mar 31, 2026 | -87,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Sep 30, 2025 | -834,000.00 |
| Sep 30, 2025 | -834,000.00 |
| Jun 30, 2025 | 419,000.00 |
| Jun 30, 2025 | 419,000.00 |
| Mar 31, 2025 | 171,000.00 |
| Mar 31, 2025 | 171,000.00 |
| Dec 31, 2024 | -1.22 Mn |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | 880,000.00 |
| Sep 30, 2024 | 880,000.00 |
| Jun 30, 2024 | -877,000.00 |
| Jun 30, 2024 | -877,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Dec 31, 2023 | -92,000.00 |
| Dec 31, 2023 | -92,000.00 |